Form 4: Supernus Pharmaceuticals SVP Jonathan Rubin Reports Stock Disposals for Tax Obligations
SEC Form 4 Filing
Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, reported the disposal of common stock to cover tax withholding requirements related to vesting Restricted Stock Units.
Summary
- On March 5, 2025, Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, disposed of shares of common stock to satisfy tax withholding requirements.
- A total of 1,468 shares were disposed of at a price of $33.05 per share.
- Following these transactions, Rubin directly owns 9,635 shares of Supernus Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing relates to routine tax-related stock disposals.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. Disposals for tax obligations are common when restricted stock units vest.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine disposal for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of stock disposal for tax withholding. |
Keywords
Form 4, Supernus Pharmaceuticals, SUPN, Jonathan Rubin, SVP, Chief Medical Officer, Stock Disposal, Tax Withholding, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.